Graves' disease

Disease ID:405
Name:Graves' disease
Associated with:1 targets
0 immuno-relevant targets
2 immuno-relevant ligands
Database Links
Disease Ontology: DOID:12361


References:  1-2


Ligand Approved Immuno References Clinical comments
Clinical Use: CFZ533 is being evaluated in clinical trials as a therapy for some autoimmune conditions and for preventing/reducing solid organ transplant rejection. Click here to link to's full list of CFZ533 trials.
Immuno Disease Comments: Phase 2 clinical candidate for Graves' disease- see NCT02713256
methimazole  [  ( ]
Clinical Use: Used in the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.
Immuno Disease Comments: Approved antithyroid drug that reduces serum CXCL10 levels and inhibits the inflammatory processes underlying autoimmune thyroid disease.


Show »

1. Chu X, Shen M, Xie F, Miao XJ, Shou WH, Liu L, Yang PP, Bai YN, Zhang KY, Yang L et al.. (2013) An X chromosome-wide association analysis identifies variants in GPR174 as a risk factor for Graves' disease. J. Med. Genet., 50 (7): 479-85. [PMID:23667180]

2. Zhao SX, Xue LQ, Liu W, Gu ZH, Pan CM, Yang SY, Zhan M, Wang HN, Liang J, Gao GQ et al.. (2013) Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis. Hum. Mol. Genet., 22 (16): 3347-62. [PMID:23612905]